

INTELGENX CORP. (IGX – TSXV) – \$1.44

“ Cutting edge Oral thin film technology ”

- IGX begin phase 2 trial for Montelukast against Alzheimer disease
- Sign agreement with U.S TILRAY ... to develop versa film products
- Very Volatile over the last 4 trading session
- IGX was up \$1.25 on Tilray news ... lost \$1.15 on the second and third day
- The stock traded over 7.5 Million shares between \$1.10 and \$2.38 cents
- (RSI = 41) ... IGX should follow Tilray volatility in the market ...
- Support; S3; \$1.10 – S2; \$1.20 - S1; \$1.35 Resistance; R1; \$1.50 – R2; \$1.80



PLEASE DO YOUR DUE DILIGENCE

Disclaimer:

This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this report.

To be removed from distribution list, reply with 'unsubscribe' in the subject line.